MedTrace Logo

Mepolizumab: Real World Evidence Study for the Treatment of Severe Eosinophilic Asthma in Greece

NCT04084613 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2019-09-12

No results posted yet for this study

Summary

A prospective multi-centre, non-interventional observational study, that will be conducted in several centers in Greece for a 2-year time period (completion date December 2020), to describe patient characteristics, medical history, and the clinical benefit of mepolizumab in patients with severe eosinophilic asthma newly initiated to the drug.

Conditions

  • Severe Eosinophilic Asthma

Sponsors & Collaborators

  • Attikon Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2020-12-31
Completion
2020-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04084613 on ClinicalTrials.gov